# Presentation: 832563

## Influenza Vaccine Responses 

**Zhiping Ye, M.D., Ph.D.**
**Division of Viral Products**

**Prepared for **
**Vaccines and Related Biological **
**Products Advisory Committee**
**17 February 2006**

**1**

## 2005-2006 Vaccine Responses to Recent Influenza isolates

- Panels of sera obtained from 2005-2006 influenza vaccinees were tested for their ability to inhibit heamagglutination of current influenza isolates
- Post-vaccination antibody titer of current virus isolates compared to vaccine strain of virus (**bold**)
- Lower titers (*italic*) indicate poor antibody inhibition of tested virus isolates

**2**

## Serum Panels for Serologies

**1. AUSTRALIA **
**IAN BARR, PH.D. ****	****	****ADULTS ****	****	****A/NEW CALEDONIA/20/99 (H1N1) **
**WHO, AUSTRALIA ****	****	****ELDERLY ****	****	****A/WELLINGTON/01/04 (H3N2) **
**	****	****	****	****	****	****B/JIANSU/10/03 **
**2. EUROPE **
**JOHN WOOD, PH.D. ****	****	****ADULTS ****	****	****A/NEW CALEDONIA/20/99 (H1N1) **
**NIBSC, ENGLAND ****	****	****ELDERLY ****	****	****A/NEW YORK/55/04 (H3N2) **
**	****	****	****	****	****	****B/JIANGSU/10/03 **
**3. JAPAN **
**TAKATO ODIGARI, PH.D. ****	****ADULTS ****	****	****A/NEW CALEDONIA/20/99 (H1N1) **
**NIID, JAPAN ****	****	****ELDERLY ****	****	****A/NEW YORK/55/04 (H3N2) **
**	****	****	****	****	****	****B/SHANGHAI/361/02**
** **
**4. STEFAN GRAVENSTEIN, M.D. ADULTS ****	****	****A/NEW CALEDONIA/20/99 (H1N1) **
**EASTERN VIRGINIA ****	****	****ELDERLY ****	****	****A/NEW YORK/55/04 (H3N2) **
**MEDICAL SCHOOL, ****	****	****PEDIATRIC ****	****B/JIANGSU/10/03 **
**USA **

**3**

## ANTIGENS FOR SEROLOGIES (H3N2)

- _VACCINE STRAIN_
**A/New York/55/04 X-157**
- _REPRESENTATIVE CURRENT STRAINS_
- A/Wisconsin/76/05
- A/Hiroshima/52/05
- A/Anhui/1239/05
- A/Brazil/1742/05
- A/North Carolina/13/05
- A/Sydney/545/05
- A/Lyon/21/06
- A/Norway/28/06
- A/Gunama/16/05
- A/Nagasaki/50/05

**4**

## HI ANTIBODY RESPONSES TO THE H3N2 COMPONENT2005-2006 INFLUENZA VACCINEPEDIATRIC POPULATION 

**5**

## HI ANTIBODY RESPONSES TO THE H3N2 COMPONENT2005-2006 INFLUENZA VACCINEADULT POPULATION ( CBER )

**6**

## A/NEW YORK/55/2004 VACCINESSUMMARY TABLE (ADULT)VIRUSES WITH > 50% GMT REDUCTION

**7**

## ANTIGENS FOR SEROLOGIES (B)

- VACCINE STRAIN
**	****B/JIANGSU/10/2003***** **
- REPRESENTATIVE CURRENT STRAINS
**	**B/FLORIDA/7/2004*		B/KITAKYUSYU/5/2005*
- 	B/GANSU/9/2005*		B/PHILIPPINES/1401/2005*
- 	B/MADAGASCAR/1509/2005*	B/EGYPT/144/2005*
**	**B/MALAYSIA/2506/2004+** ****	**B/OHIO/1/2005+
- 	B/GUANGONG/321/2005+	B/ENGLAND/458/2005+
- 	B/SINGAPORE/21/2005+
- * B/YAMAGATA LINEAGE
- + B/VICTORIA LINEAGE

**8**

## HI ANTIBODY RESPONSES TO THE B COMPONENT2005-2006 INFLUENZA VACCINEPEDIATRIC POPULATION  

**9**

## HI ANTIBODY RESPONSES TO THE B COMPONENT2005-2006 INFLUENZA VACCINEADULT POPULATION (CDC)

**10**

## B/JANGSU/10/2003-LIKE VACCINESSUMMARY TABLEVIRUSES WITH > 50% GMT REDUCTION (ADULT)

**11**

## Influenza Vaccine ResponsesSummary

- Studies with sera collected after immunization with current vaccines show that:
- H1
- Representative recent viruses well inhibited (data not shown)
- H3
- A/WISCONSIN/67/2005 (H3N2)-like viruses less well
- inhibited compared to the vaccine strain
- B
- B/YAMAGATA/16/88-lineage
- Representative recent viruses generally well inhibited compared to the vaccine strain
- B/VICTORIA/2/87-lineage
- Representative B/Malaysia/2506/2004-like viruses poorly inhibited compared to the vaccine strain

**12**